Search Patents
  • Test and model for alzheimer's disease
    Publication number: 20020133834
    Abstract: The invention provides an isolated nucleic acid characteristic of human amyloid precursor protein 770 including the nucleotides encoding codon 670 and 671, wherein the nucleic acid encodes an amino acid other than lysine at codon 670 and/or an amino acid other than methionine at codon 671. Also provided is a method of diagnosing or predicting a predisposition to Alzheimer's disease, comprising detecting in a sample from a subject the presence of a mutation at a nucleotide position corresponding to codons 670 and/or 671 of amyloid precursor protein or fragment thereof, the presence of the mutation indicating the presence of or a predisposition to Alzheimer's disease.
    Type: Application
    Filed: February 16, 2001
    Publication date: September 19, 2002
    Applicant: Alzheimer's Institute of America, Inc.
    Inventor: Michael John Mullan
  • Amyloid precursor protein in alzheimer's disease
    Patent number: 5795963
    Abstract: The invention provides an isolated nucleic acid characteristic of human amyloid precursor protein 770 including the nucleotides encoding codon 670 and 671, wherein the nucleic acid encodes an amino acid other than lysine at codon 670 and/or an amino acid other than methionine at codon 671. Also provided is a method of diagnosing or predicting a predisposition to Alzheimer's disease, comprising detecting in a sample from a subject the presence of a mutation at a nucleotide position corresponding to codons 670 and/or 671 of amyloid precursor protein or fragment thereof, the presence of the mutation indicating the presence of or a predisposition to Alzheimer's disease.
    Type: Grant
    Filed: March 13, 1997
    Date of Patent: August 18, 1998
    Assignee: Alzheimer's Institute of America
    Inventor: Michael John Mullan
  • Nucleic acids for diagnosing and modeling Alzheimer's disease
    Patent number: 5455169
    Abstract: The invention provides an isolated nucleic acid characteristic of human amyloid precursor protein 770 including the nucleotides encoding codon 670 and 671, wherein the nucleic acid encodes an amino acid other than lysine at codon 670 and/or an amino acid other than methionine at codon 671. Also provided is a method of diagnosing or predicting a predisposition to Alzheimer's disease, comprising detecting in a sample from a subject the presence of a mutation at a nucleotide position corresponding to codons 670 and/or 671 of amyloid precursor protein or fragment thereof, the presence of the mutation indicating the presence of or a predisposition to Alzheimer's disease.
    Type: Grant
    Filed: June 4, 1992
    Date of Patent: October 3, 1995
    Assignee: Alzheimer's Institute of America, Inc.
    Inventor: Michael J. Mullan
  • Alzheimer's disease-specific alterations of the ERK1/ERK2 Phosphorylation ratio-Alzheimer's disease-specific molecular biomarkers (ADSMB)
    Publication number: 20080221042
    Abstract: The present invention relates to methods of diagnosing Alzheimer's Disease as well as to methods of confirming the presence or absence of Alzheimer's Disease in a subject. The present invention is also directed to methods of identifying a lead compound useful for the treatment of Alzheimer's Disease by contacting non-Alzheimer's cells with an amyloid beta peptide, stimulating the cells with a protein kinase C activator, contacting the cells with a test compound, and determining the value of an Alzheimer's Disease-specific molecular biomarker. The present invention is also directed to methods of diagnosing Alzheimer's Disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator.
    Type: Application
    Filed: April 7, 2008
    Publication date: September 11, 2008
    Inventors: Tapan Kumar Khan, Daniel L. Alkon
  • ALZHEIMER'S DISEASE-SPECIFIC ALTERATIONS OF THE ERK1/ERK2 PHOSPHORYLATION RATIO-ALZHEIMER'S DISEASE-SPECIFIC MOLECULAR BIOMARKERS (ADSMB)
    Publication number: 20180024146
    Abstract: The present invention relates to methods of diagnosing Alzheimer's Disease as well as to methods of confirming the presence or absence of Alzheimer's Disease in a subject. The present invention is also directed to methods of identifying a lead compound useful for the treatment of Alzheimer's Disease by contacting non-Alzheimer's cells with an amyloid beta peptide, stimulating the cells with a protein kinase C activator, contacting the cells with a test compound, and determining the value of an Alzheimer's Disease-specific molecular biomarker. The present invention is also directed to methods of diagnosing Alzheimer's Disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator.
    Type: Application
    Filed: September 29, 2017
    Publication date: January 25, 2018
    Inventors: Tapan Kumar Khan, Daniel L. Alkon
  • NOVEL BIOMARKER FOR DIAGNOSIS OF ALZHEIMER'S DISEASE, DISCOVERED FROM BLOOD-DERIVED EXOSOMES, AND METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE USING SAME
    Publication number: 20240053365
    Abstract: The present invention relates to a novel exosome-derived biomarker for diagnosis of Alzheimer's disease, a composition for diagnosis of Alzheimer's disease containing the biomarker, a kit for diagnosis of Alzheimer's disease including the composition, and a method for providing information for diagnosis of Alzheimer's disease using the biomarker, composition, or kit. The biomarker for diagnosis of Alzheimer's disease provided by the present invention can be widely utilized for effective diagnosis of Alzheimer's disease and further for treatment of Alzheimer's disease since not only the diagnostic rate of Alzheimer's disease can be increased but also the accuracy, sensitivity, and specificity can be increased through subdivided diagnosis according to the progression stages (healthy, MCI, and AD) of Alzheimer's disease by using the biomarker.
    Type: Application
    Filed: November 30, 2021
    Publication date: February 15, 2024
    Inventors: So Youn Kim, Gunjoo Park
  • ALZHEIMER'S DISEASE-SPECIFIC ALTERATIONS OF THE ERK1/ERK2 PHOSPHORYLATION RATIO-ALZHEIMER'S DISEASE-SPECIFIC MOLECULAR BIOMARKERS (ADSMB)
    Publication number: 20140031245
    Abstract: The present invention relates to methods of diagnosing Alzheimer's Disease as well as to methods of confirming the presence or absence of Alzheimer's Disease in a subject. The present invention is also directed to methods of identifying a lead compound useful for the treatment of Alzheimer's Disease by contacting non-Alzheimers cells with an amyloid beta peptide, stimulating the cells with a protein kinase C activator, contacting the cells with a test compound, and determining the value of an Alzheimer's Disease-specific molecular biomarker. The present invention is also directed to methods of diagnosing Alzheimer's Disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator.
    Type: Application
    Filed: February 22, 2013
    Publication date: January 30, 2014
    Applicant: BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE
    Inventor: BLANCHETTE ROCKEFELLER NEUROSCIENCE INSTITUTE
  • Alzheimer's disease-specific alterations of the ERK1/ERK2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (ADSMB)
    Patent number: 9797913
    Abstract: The present invention relates to methods of diagnosing Alzheimer's Disease as well as to methods of confirming the presence or absence of Alzheimer's Disease in a subject. The present invention is also directed to methods of identifying a lead compound useful for the treatment of Alzheimer's Disease by contacting non-Alzheimers cells with an amyloid beta peptide, stimulating the cells with a protein kinase C activator, contacting the cells with a test compound, and determining the value of an Alzheimer's Disease-specific molecular biomarker. The present invention is also directed to methods of diagnosing Alzheimer's Disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: October 24, 2017
    Assignee: Blanchette Rockefeller Neuroscienses Inc.
    Inventors: Tapan Kumar Khan, Daniel L. Alkon
  • Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
    Publication number: 20090029873
    Abstract: The present invention relates to methods of diagnosing Alzheimer's Disease as well as to methods of confirming the presence or absence of Alzheimer's Disease in a subject. The present invention is also directed to methods of identifying a lead compound useful for the treatment of Alzheimer's Disease by contacting non-Alzheimer's cells with an amyloid beta peptide, stimulating the cells with a protein kinase C activator, contacting the cells with a test compound, and determining the value of an Alzheimer's Disease-specific molecular biomarker. The present invention is also directed to methods of diagnosing Alzheimer's Disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator.
    Type: Application
    Filed: September 25, 2006
    Publication date: January 29, 2009
    Inventors: Tapan Kumar Khan, Daniel L. Alkon
  • ARTIFICIAL INTELLIGENCE AND BLOOD EPIGENOMIC ANALYSIS FOR ALZHEIMERS DISEASE
    Publication number: 20220002808
    Abstract: An Artificial intelligence-based method for diagnosing Alzheimer's Disease or determining susceptibility to Alzheimer's Disease includes a step of obtaining a blood sample from a target subject (e.g., a human). The degree of methylation in one or a plurality of Alzheimer indicators genes is identified for leukocytes in the blood sample. Each Alzheimer indicator gene is identified as being an indicator of the presence of or risk of developing Alzheimer's Disease. Characteristically, the at least one or the plurality of Alzheimer indicators genes have been identified by a machine learning technique or by logistic regression. Finally, the target subject is identified as being at risk for Alzheimer's Disease if the amount of methylation of one or more Alzheimer indicators genes differs from the amount of methylation established in control subjects (for the same genes) not having Alzheimer's Disease by a predetermined amount.
    Type: Application
    Filed: July 2, 2021
    Publication date: January 6, 2022
    Inventors: Ray BAHADO-SINGH, Sangeetha VISHWESWARAIAH, Uppala RADHAKRISHNA, Stewart Francis GRAHAM
  • Alzheimer's disease-specific alterations of the ERK1/ERK2 phosphorylation ratio
    Publication number: 20070082366
    Abstract: The present invention is directed to methods of diagnosing Alzheimer's disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator. The Alzheimer's disease-specific molecular biomarkers disclosed herein are useful for the diagnosis of Alzheimer's disease, monitoring the progression of Alzheimer's disease in a subject and in screening methods for the identification of compounds for treating or preventing Alzheimer's disease. The invention is also directed to kits containing reagents for the detection and diagnosis of Alzheimer's disease using the Alzheimer's disease-specific molecular biomarkers disclosed herein.
    Type: Application
    Filed: October 11, 2005
    Publication date: April 12, 2007
    Inventors: Tapan Khan, Daniel Alkon
  • SPECTROSCOPIC METHOD FOR ALZHEIMER'S DISEASE DIAGNOSIS
    Publication number: 20150276482
    Abstract: The present invention relates to a method for detecting Alzheimer's disease in a subject. This method involves providing a sample from the subject, subjecting the sample to a spectroscopic analysis to produce a spectroscopic signature for the sample, determining whether the spectroscopic signature for the sample corresponds to an Alzheimer's disease spectroscopic signature, and identifying a subject as having Alzheimer's disease where the spectroscopic signature for the sample from that subject corresponds to the spectroscopic signature for Alzheimer's disease.
    Type: Application
    Filed: October 2, 2013
    Publication date: October 1, 2015
    Inventor: Igor K. Lednev
  • Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
    Patent number: 7595167
    Abstract: The present invention is directed to a method of diagnosing Alzheimer's disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator. The Alzheimer's disease-specific molecular biomarkers disclosed herein are useful for the diagnosis of Alzheimer's disease, monitoring the progression of Alzheimer's disease in a subject and in screening methods for the identification of compounds for treating or preventing Alzheimer's disease. The invention is also directed to kits containing reagents for the detection and diagnosis of Alzheimer's disease using the Alzheimer's disease-specific molecular biomarkers disclosed herein.
    Type: Grant
    Filed: October 11, 2005
    Date of Patent: September 29, 2009
    Assignee: Blanchette Rockefeller Neurosciences Institute
    Inventors: Tapan Kumar Khan, Daniel L. Alkon
  • Spectroscopic method for Alzheimer's disease diagnosis
    Patent number: 9891108
    Abstract: The present invention relates to a method for detecting Alzheimer's disease in a subject. This method involves providing a sample from the subject, subjecting the sample to a spectroscopic analysis to produce a spectroscopic signature for the sample, determining whether the spectroscopic signature for the sample corresponds to an Alzheimer's disease spectroscopic signature, and identifying a subject as having Alzheimer's disease where the spectroscopic signature for the sample from that subject corresponds to the spectroscopic signature for Alzheimer's disease.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: February 13, 2018
    Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventor: Igor K. Lednev
  • CELLULAR MARKERS FOR DIAGNOSIS OF ALZHEIMER'S DISEASE AND FOR ALZHEIMER'S DISEASE PROGRESSION
    Publication number: 20150057176
    Abstract: The present invention provides methods for early diagnosis of Alzheimer's disease and for determining the efficacy of a treatment for Alzheimer's disease in an Alzheimer's patient, i.e., monitoring Alzheimer's disease progression, utilizing cellular blood markers; as well as kits for carrying out these methods.
    Type: Application
    Filed: March 21, 2013
    Publication date: February 26, 2015
    Inventors: Michal Eisenbach-Schwartz, Ester Yoles
  • Alzheimer's Disease Cellular Model for Diagnostic and Therapeutic Development
    Publication number: 20140011197
    Abstract: Stem-cell derived human neuronal models that mimic human Alzheimer's disease, including hereditary and sporadic Alzheimer's disease, comprising neural stem cells derived from human induced pluripotent stem cells. Also provided are purified human neurons developed from the neural stem cells that carry genomes from the Alzheimer's disease patients. The human neuronal models are neuronal models for hereditary and sporadic Alzheimer's disease, and are suitable for measurement of key behaviors of the Alzheimer's disease, providing further diagnostic tools for the development of sporadic Alzheimer's disease, and assisting in drug testing for the therapeutic treatment of Alzheimer's disease.
    Type: Application
    Filed: August 15, 2013
    Publication date: January 9, 2014
    Applicant: The Regents of the University of California
    Inventors: Lawrence Goldstein, Mason Israel
  • METHOD OF DIAGNOSING ALZHEIMER'S DISEASE USING GIANT MAGNETORESISTANCE SENSOR AND MAGNETIC BEAD-POLYPROTEIN COMPLEX FOR DIAGNOSING ALZHEIMER'S DISEASE
    Publication number: 20110244484
    Abstract: Provided are a method of diagnosing Alzheimer's disease using a giant magnetoresistance sensor and a magnetic bead-polyprotein complex for diagnosing Alzheimer's disease. The method of diagnosing Alzheimer's disease using the giant magnetoresistance sensor may be applied to diagnose Alzheimer's disease more easily and simply using the giant magnetoresistance sensor than using conventional fluorescent materials or genetic analyses, and the magnetic bead-polyprotein complex may be mass-produced as a diagnostic biosensor for Alzheimer's disease, and thus to be useful to monitor and treat Alzheimer's disease.
    Type: Application
    Filed: April 1, 2011
    Publication date: October 6, 2011
    Applicant: ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE
    Inventors: Cheol-Joo CHAE, Kwan-Su Kim, Jae-Min Kang, Jeong-Dae Suh, Myung-Ae Chung, Ki-Bong Song
  • BIOMARKERS AND USES THEREOF FOR DIAGNOSING THE SILENT PHASE OF ALZHEIMER'S DISEASE
    Publication number: 20210325409
    Abstract: The present invention relates to a molecular signature of the silent phase of Alzheimer's disease; and to methods using the same, for diagnosing a silent stage of Alzheimer's disease in a subject, stratifying a silent phase of Alzheimer's disease in a subject into different grades of the silent phase, prognosticating the progress of a silent phase of Alzheimer's disease in a subject, and determining a personalized course of treatment in a subject affected with a silent phase of Alzheimer's disease, it also relates to a computer system comprising a machine learning algorithm trained for diagnosing a silent phase of Alzheimer's disease in a subject.
    Type: Application
    Filed: April 22, 2021
    Publication date: October 21, 2021
    Inventors: Jérôme BRAUDEAU, Baptiste BILLOIR, Benoît SOUCHET, Alkéos Michaïl
  • MICRORNA BIOMARKERS INDICATIVE OF ALZHEIMER'S DISEASE
    Publication number: 20140378439
    Abstract: The invention provides a method of diagnosing Alzheimer's Disease in a subject, by determining the level of at least one miRNA in a sample derived from the subject, wherein a change in the level of the at least one miRNA relative to a suitable control is indicative of Alzheimer's Disease in the subject. Methods for monitoring the course of Alzheimer's Disease, methods of treating a subject having Alzheimer's Disease, and kits for diagnosing Alzheimer's Disease are also provided.
    Type: Application
    Filed: June 26, 2012
    Publication date: December 25, 2014
    Inventors: Zoltan Dezso, Pavan Kumar
  • Diagnostic test for alzheimers disease
    Patent number: 6107050
    Abstract: The present invention provides methods for the diagnosis of Alzheimer's disease using human cells. Specifically, one method detects differences between potassium channels in cells from Alzheimer's patient and normal donors, and differences in intracellular calcium concentrations between Alzheimer's and normal cells in response to chemicals known to increase intracellular calcium levels. Other methods detect differences between the memory associated GTP binding Cp20 protein levels between Alzheimer's and normal cells. Another method utilizes the differential effects of .beta.-amyloid protein on levels of the protein kinase C isoenzymes PKC.alpha. and PKC.gamma. in Alzheimer's and normal cells. Yet another method detects Eu-TTA fluorescence differences between Alzheimer's and normal cells treated with an activator of a receptor-mediated metabolic pathway. In addition a diagnostic index for improved assessment between Alzheimer's and non Alzheimer's cells is provided.
    Type: Grant
    Filed: May 11, 1998
    Date of Patent: August 22, 2000
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Daniel L. Alkon, Antonelle R. Favit, Maurizio Grimaldi
Narrow Results

Filter by US Classification